We evaluated the effects of amiodarone in 45 patients with recurrent ventricular tachycardia or ventricular fibrillation. At a mean follow-up time of 12.7 +/- 8.8 months (range, three to 36), amiodarone was successful in nine of 16 patients with recurrent ventricular fibrillation and 21 of 29 with recurrent ventricular tachycardia. During amiodarone therapy, ventricular tachycardia could be induced in 18 of 19 patients in whom it had been induced before therapy, but only six of these 19 had spontaneous recurrence during follow-up. Side effects included corneal microdeposits, hyperthyroidism, blue skin, nausea, and symptomatic bradycardia. Pulmonary fibrosis occurred in three patients. Doses of up to 2000 mg a day did not produce cardiac toxicity, but neurologic side effects precluded long-term therapy at this dose. We conclude that amiodarone is effective for long-term therapy of recurrent ventricular tachyarrhythmias, that induction of arrhythmia during therapy does not always predict efficacy, and that side effects are frequent but do not usually limit therapy.
This article has been cited by other articles:
The International Liaison Committee on Resuscitati,
(2006). The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support. Pediatrics
117: e955-e977
[Abstract][Full Text]
(2005). Part 6: Pediatric Basic and Advanced Life Support. Circulation
112: III-73-III-90
[Full Text]
Ott, M. C., Khoor, A., Leventhal, J. P., Paterick, T. E., Burger, C. D.
(2003). Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone. Chest
123: 646-651
[Abstract][Full Text]
Poll, L. W., May, P., Koch, J.-A., Hetzel, G., Heering, P., Modder, U.
(2001). HRCT Findings of Amiodarone Pulmonary Toxicity: Clinical and Radiologic Regression. J CARDIOVASC PHARMACOL THER
6: 307-311
[Abstract]
Bolt, M. W., Card, J. W., Racz, W. J., Brien, J. F., Massey, T. E.
(2001). Disruption of Mitochondrial Function and Cellular ATP Levels by Amiodarone and N-Desethylamiodarone in Initiation of Amiodarone-Induced Pulmonary Cytotoxicity. J. Pharmacol. Exp. Ther.
298: 1280-1289
[Abstract][Full Text]
Connolly, S. J.
(1999). Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation
100: 2025-2034
[Full Text]
Kovoor, P., Eipper, V., Byth, K., Cooper, M.J., Uther, J.B., Ross, D.L.
(1999). Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J
20: 364-374
[Abstract]
Kuhlkamp, V., Mewis, C., Mermi, J., Bosch, R. F., Seipel, L.
(1999). Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol
33: 46-52
[Abstract][Full Text]
Nalos, P. C., Myers, M. R., Gang, E. S., Peter, T., Mandel, W. J.
(1987). Analytic Reviews: Electrophysiologic Testing in the Intensive Care Unit. J Intensive Care Med
2: 241-259
[Abstract]
Herre, J. M.
(1987). Advances in the Management of Tachyarrhythmias. J Intensive Care Med
2: 65-75
[Abstract]
Previous
